News
SXTPW
0.0393
0.00%
0.0000
60 Degrees announces early enrollment of first patient in trial of tafenoquine
TipRanks · 4d ago
60 Degrees Pharma enrolls first patient in tafenoquine babesiosis trial in US Northeast hospitals
PUBT · 4d ago
60 DEGREES PHARMACEUTICALS ANNOUNCES EARLY ENROLLMENT OF FIRST SEASONAL PATIENT IN CLINICAL TRIAL OF TAFENOQUINE FOR PATIENTS HOSPITALIZED WITH BABESIOSIS
Reuters · 4d ago
Weekly Report: what happened at SXTP last week (0518-0522)?
Weekly Report · 5d ago
60 Degrees Pharm Price Target Cut to $3.70/Share From $4.20 by Ascendiant Capital
Dow Jones · 05/22 12:06
60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital
Dow Jones · 05/22 12:06
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7
Benzinga · 05/22 11:56
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, Nvidia
Reuters · 05/21 06:42
60 DEGREES PHARMACEUTICALS INC <SXTP.O>: H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY
Reuters · 05/21 03:16
60 Degrees Pharm Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 05/20 17:13
HC Wainwright & Co. Downgrades 60 Degrees to Neutral
Benzinga · 05/20 17:03
H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending
TipRanks · 05/20 16:00
60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 05/20 15:55
60 Degrees Pharma director Eric Francois files initial beneficial ownership statement
PUBT · 05/19 22:14
60 Degrees Pharma appoints Eric Francois to board
PUBT · 05/18 20:33
Weekly Report: what happened at SXTP last week (0511-0515)?
Weekly Report · 05/18 10:25
60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate
Benzinga · 05/15 13:29
Press Release: 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Dow Jones · 05/15 12:42
60 Degrees Pharma net loss widens to $2.09 million in Q1 FY26; product revenues slip 0.89% to $162,092
PUBT · 05/15 12:12
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
Barchart · 05/15 07:42
More
Webull provides a variety of real-time SXTPW stock news. You can receive the latest news about 60 Degrees Pharm through multiple platforms. This information may help you make smarter investment decisions.
About SXTPW
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.